Sarcoma

Official Title: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Study Purpose: To compare the progression free survival (PFS)  and the overall survival (OS)of olaparib plus temozolomide (Arm 1) as compared to investigator’s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uterine leiomyosarcoma who have received two or more prior lines of therapy as determined by investigator (local site) assessment.

Status: Recruiting

Official Title: A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma 

Study Purpose: Is the combination of palbociclib plus cemiplimab better than palbociclib alone in the treatment of advanced dedifferentiated liposarcoma that cannot be removed by surgery

Status: Recruiting

Official Title: Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma 

Study Purpose: The primary objective is to evaluate the safety of brigimadlin in patients with advanced or metastatic DDLPSThe secondary objectives are to evaluate efficacy by using objective response (OR), duration of objective response (DOR), PFS, and overall survival (OS), and to further assess safety.

Status: Recruiting

Official Title: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS 

Study Purpose: The purpose of this part of the research study is to evaluate how CGT9486 plus sunitinib affects GIST compared to just treatment with sunitinib alone. 

Status: Recruiting

Official Title: A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen

Study Purpose: To assess how well the drug Ivosidenib works against chondrosarcoma

Status: Pending

Official Title: A Randomized, Double Blind, Placebo controlled, Phase 2 Study of INBRX 109 as Any line Therapy in Conventional Chondrosarcoma

Study Purpose: To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat population as measured by progression free survival assessed by central independent radiology review comparing INBRX-109 and placebo.

Status: Recruiting

Official Title: A Multicenter, Randomized, Phase III Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With Standard of Care in Adult participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL) 

Study Purpose: To evaluate the effectiveness of IT-03 compared to the usual treatment of pazopanib, trabectedin or eribulin 

Status: Pending